The Overactive Bladder drugs in development market research report provides comprehensive information on the therapeutics under development for Overactive Bladder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Overactive Bladder. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued products.
GlobalData tracks 30 drugs in development for Overactive Bladder by 32 companies/universities/institutes. The top development phase for Overactive Bladder is preclinical with 13 drugs in that stage. The Overactive Bladder pipeline has 29 drugs in development by companies and one by universities/ institutes. Some of the companies in the Overactive Bladder pipeline products market are: Kissei Pharmaceutical, Aetas Pharma and Taiho Pharmaceutical.
The key targets in the Overactive Bladder pipeline products market include Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8), Muscarinic Acetylcholine Receptor M3 (CHRM3), and Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3).
The key mechanisms of action in the Overactive Bladder pipeline product include Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) Agonist with three drugs in Pre-Registration. The Overactive Bladder pipeline products include eight routes of administration with the top ROA being Oral and three key molecule types in the Overactive Bladder pipeline products market including Small Molecule, and Peptide.
Overactive Bladder overview
Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feeling a sudden urge to urinate that’s difficult to control, experiencing urge incontinence, and awakening two or more times in the night to urinate. Treatment includes changes in lifestyle, and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.
For a complete picture of Overactive Bladder’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
